clinical trial · NCT06116786
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Johnson & Johnson Enterprise Innovation Inc.·phase1·recruiting·n = 126
Carcinoma, Non-small-Cell LungJNJ-86974680CetrelimabRadiation Therapy
brief summary
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
started
Nov 27, 2023
primary completion
Apr 14, 2027
completion
Jun 7, 2029
last updated
Apr 13, 2026
official title
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol